TTRX 8-K SEC Filing Analysis

Latest settled — T+5d

TTRX ▲ +13.80% at T+5d

LONG call ✓ call won +13.80% · α vs SPY +13.33% · entry $5.29 → $6.02

Next anchor: T+20d in 12d

Currently $6.05 · +14.27% from $5.29 entry

Entry anchored
May 26, 03:39 PM ET
via Databento tick

T+1d

+0.38%

call +0.38% · α -0.17%

$5.31

settled 16d ago

T+5d

+13.80%

call +13.80% · α +13.33%

$6.02

settled 10d ago

T+20d

—

call — · α —

—

in 12d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Turn Therapeutics announced a peer-reviewed publication in the Journal of Dermatological Treatment showing that GX-03 achieved a statistically significant reduction in disease severity in a murine dermatitis model characterized by IL-36 expression. This is the first in a planned series of publications supporting the scientific rationale for GX-03, which is currently in Phase 2 evaluation for moderate-to-severe atopic dermatitis with topline results expected in mid-2026.

Actionable Insight

The publication provides incremental scientific validation for GX-03's mechanism but does not change the binary Phase 2 readout expected mid-2026. Monitor for the subsequent mechanistic manuscript and the Phase 2 topline results as the next major catalysts.

Key Facts

GX-03 achieved mean IGA score of 1.44 vs 3.00 in controls (p=0.0003) in murine IL-36 model
No treatment-related adverse effects observed
First in a planned series of peer-reviewed publications on GX-03
GX-03 currently in Phase 2 RCT for moderate-to-severe atopic dermatitis; topline results expected mid-2026
Subsequent manuscript already in review characterizing mechanistic implications

Financial Impact

No financial data provided; pre-revenue clinical-stage biotech with $171M market cap

Risk Factors

Preclinical murine data may not translate to human clinical outcomes
Phase 2 topline results are the true catalyst; publication alone does not de-risk the program
Clinical-stage biotech with no approved products or revenue

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

86% bullish (7 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001213900-26-061244
Document: ea029186601ex99-1.htm	0001213900-26-061244
Document: 0001213900-26-061244-index-headers.html	0001213900-26-061244
Document: 0001213900-26-061244-index.html	0001213900-26-061244
Document: 0001213900-26-061244.txt	0001213900-26-061244

8 reports for TTRX

T+1T+5T+20T+60

75% Hit rate 3 of 4 directional calls best @ T+5▲ +9.39%May 18, 2026

Filters

Reports for TTRX — sortable, filterable
	Type				Now
Jun 3, 2026 9d ago	8-K BULLISH ★ 7/10	$6.02 $5.75	▼ −4.57%	▼ −4.97%	$6.05 (+0.42%)
Jun 1, 2026 11d ago	8-K BULLISH ★ 6/10	$6.33 $6.42	▲ +1.42%	▲ +1.28%	$6.05 (−4.50%)
May 27, 2026 16d ago	8-K BULLISH ★ 5/10	$5.29 $5.31	▲ +0.38%	▼ −0.17%	$6.05 (+14.27%)
May 19, 2026 24d ago	8-K NEUTRAL ★ 2/10	$4.55 $4.76	▲ +4.62%	▲ +3.58%	$6.05 (+32.86%)
May 18, 2026 25d ago	8-K BULLISH ★ 5/10	$4.90 $4.55	▼ −7.14%	▼ −6.49%	$6.05 (+23.37%)
May 11, 2026 4w ago	8-K NEUTRAL ★ 4/10	$3.98 $3.98	· 0.00%	▼ −0.54%	$6.05 (+51.88%)
Apr 3, 2026 10w ago	EFFECT BEARISH ★ 7/10	$3.33 $3.36	▼ −0.90%	▼ −0.84%	$6.05 (−81.53%)
Mar 31, 2026 10w ago	8-K MIXED ★ 6/10	$3.12 $3.35	▲ +7.54%	▲ +7.46%	$6.05 (+94.06%)

US Market Status

Market Closed — Opens Mon (52h 18m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access